lisdexamfetamine mesylate
PolandDrugs containing this active substance
-
The medicine is used as part of the comprehensive treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 18 years (if previous treatment with methylphenidate has not helped) and in adults who have had ADHD since childhood.
Form: capsules, hard
Active substance Dosage lisdexamfetamine mesylate 30 mg ATC: N06BA12
Manufacturer: Shire Pharmaceuticals Ireland Limited Takeda GmbH Takeda Pharmaceuticals International AG Ireland Branch
-
The medicine is used as part of the comprehensive treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 18 years (if methylphenidate has not been effective) and in adults who have had ADHD since childhood.
Form: capsules, hard
Active substance Dosage lisdexamfetamine mesylate 50 mg ATC: N06BA12
Manufacturer: Shire Pharmaceuticals Ireland Limited Takeda GmbH Takeda Pharmaceuticals International AG Ireland Branch
-
The medicine is used as part of the comprehensive treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6–18 years (if methylphenidate has not been effective) and in adults who have had ADHD since childhood. It helps to facilitate concentration and reduce hyperactivity.
Form: capsules, hard
Active substance Dosage lisdexamfetamine mesylate 70 mg ATC: N06BA12
Manufacturer: Shire Pharmaceuticals Ireland Limited Takeda GmbH Takeda Pharmaceuticals International AG Ireland Branch
-
The medicine is used as part of the comprehensive treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6–18 years (if methylphenidate has not been effective) and in adults who have had ADHD since childhood.
Form: capsules, hard
Active substance Dosage lisdexamfetamine mesylate 20 mg ATC: N06BA12
Manufacturer: Shire Pharmaceuticals Ireland Limited Takeda GmbH Takeda Pharmaceuticals International AG Ireland Branch
-
The medicine is used as part of the comprehensive treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 18 years (if methylphenidate has not been effective) and in adults who have had ADHD since childhood.
Form: capsules, hard
Active substance Dosage lisdexamfetamine mesylate 40 mg ATC: N06BA12
Manufacturer: Shire Pharmaceuticals Ireland Limited Takeda GmbH Takeda Pharmaceuticals International AG Ireland Branch
-
The medicine is used as part of the comprehensive treatment of attention deficit hyperactivity disorder (ADHD). It helps to facilitate attention, improve concentration, and reduce hyperactivity.
Form: capsules, hard
Active substance Dosage lisdexamfetamine mesylate 60 mg ATC: N06BA12
Manufacturer: Shire Pharmaceuticals Ireland Limited Takeda GmbH Takeda Pharmaceuticals International AG Ireland Branch